Spark Therapeutics (NASDAQ:ONCE)‘s stock had its “buy” rating reaffirmed by investment analysts at William Blair in a research note issued on Tuesday.
A number of other research analysts have also recently issued reports on ONCE. Credit Suisse Group lifted their price target on shares of Spark Therapeutics from $75.00 to $98.00 and gave the company an “outperform” rating in a research report on Monday, July 9th. Cantor Fitzgerald set a $103.00 price target on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Monday, July 16th. Royal Bank of Canada cut shares of Spark Therapeutics from an “outperform” rating to a “sector perform” rating and set a $100.00 price target for the company. in a research report on Thursday, July 19th. ValuEngine cut shares of Spark Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 24th. Finally, Citigroup raised shares of Spark Therapeutics from a “neutral” rating to a “buy” rating in a research report on Tuesday, August 7th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the stock. Spark Therapeutics has an average rating of “Hold” and an average target price of $70.10.
Shares of NASDAQ:ONCE traded down $2.49 on Tuesday, hitting $41.53. The company had a trading volume of 48,582 shares, compared to its average volume of 497,808. Spark Therapeutics has a 1 year low of $41.06 and a 1 year high of $96.59. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of -5.44 and a beta of 2.27.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.22). Spark Therapeutics had a negative net margin of 185.46% and a negative return on equity of 17.33%. The business had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $27.44 million. During the same period last year, the business earned ($1.90) earnings per share. The company’s revenue was up 463.2% on a year-over-year basis. On average, equities research analysts expect that Spark Therapeutics will post -1.44 earnings per share for the current fiscal year.
Institutional investors have recently modified their holdings of the business. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Spark Therapeutics in the third quarter worth about $122,000. Dynamic Technology Lab Private Ltd purchased a new position in Spark Therapeutics in the second quarter worth about $203,000. Cubist Systematic Strategies LLC purchased a new position in Spark Therapeutics in the second quarter worth about $268,000. Bank of Montreal Can raised its holdings in Spark Therapeutics by 1,045.4% in the third quarter. Bank of Montreal Can now owns 3,253 shares of the biotechnology company’s stock worth $177,000 after buying an additional 2,969 shares during the last quarter. Finally, Smith Asset Management Group LP raised its holdings in Spark Therapeutics by 39.6% in the third quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock worth $215,000 after buying an additional 1,120 shares during the last quarter.
About Spark Therapeutics
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Read More: What does the Dow Jones Industrial Average (DJIA) measure?
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.